Bart N M Van Berckel

List of Publications by Year
in descending order

135 papers	7,031 citations	76326 40 h-index	66911 78 g-index
159 all docs	159 docs citations	159 times ranked	7873 citing authors

#	Article	IF	Citations
1	Identifying best practices for disclosure of amyloid imaging results: A randomized controlled trial. Alzheimer's and Dementia, 2023, 19, 285-295.	0.8	12
2	The natural history of primary progressive aphasia: beyond aphasia. Journal of Neurology, 2022, 269, 1375-1385.	3.6	23
3	A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimerâ€™s disease, and mild cognitive impairment using brain 18F-FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 563-584.	6.4	41
4	Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1951-1963.	6.4	8
5	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	9.0	97
6	Genetically identical twins show comparable tau PET load and spatial distribution. Brain, 2022, 145, 3571-3581.	7.6	12
7	Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline. Neurology, 2022, 98, .	1.1	41
8	EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 632-651.	6.4	82
9	Impact of cerebral blood flow and amyloid load on SUVR bias. EJNMMI Research, 2022, 12, 29.	2.5	6
10	Longitudinal retinal layer changes in preclinical Alzheimerâ€™s disease. Acta Ophthalmologica, 2021, 99, 538-544.	1.1	13
11	What Determines Cognitive Functioning in the Oldest-Old? The EMIF-AD 90+ Study. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2021, 76, 1499-1511.	3.9	14
12	Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimerâ€™s Disease. Journal of the International Neuropsychological Society, 2021, 27, 426-438.	1.8	30
13	Classification of negative and positive 18F-florbetapir brain PET studies in subjective cognitive decline patients using a convolutional neural network. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 721-728.	6.4	16
14	Effect of Shortening the Scan Duration on Quantitative Accuracy of [18F]Flortaucipir Studies. Molecular Imaging and Biology, 2021, 23, 604-613.	2.6	10
15	Amyloidâ€Î², cortical thickness, and subsequent cognitive decline in cognitively normal oldestâ€old. Annals of Clinical and Translational Neurology, 2021, 8, 348-358.	3.7	9
16	White matter microstructure disruption in early stage amyloid pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12124.	2.4	16
17	Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [18F]Flortaucipir and [18F]Florbetapir Brain PET Studies. Molecular Imaging and Biology, 2021, 23, 550-559.	2.6	2
18	Contralateral improvement of cerebrovascular reactivity and TIA frequency after unilateral revascularization surgery in moyamoya vasculopathy. NeuroImage: Clinical, 2021, 30, 102684.	2.7	11

#	Article	IF	Citations
19	Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2169-2182.	6.4	24
20	Associations among education, age, and the dementia with Lewy bodies (DLB) metabolic pattern: A Europeanâ€ÐLB consortium project. Alzheimer's and Dementia, 2021, 17, 1277-1286.	0.8	5
21	In vivo tau pathology is associated with synaptic loss and altered synaptic function. Alzheimer's Research and Therapy, 2021, 13, 35.	6.2	47
22	A Comparison of Two Statistical Mapping Tools for Automated Brain FDG-PET Analysis in Predicting Conversion to Alzheimerâ€™s Disease in Subjects with Mild Cognitive Impairment. Current Alzheimer Research, 2021, 17, 1186-1194.	1.4	4
23	Molecular Imaging Approaches in Dementia. Radiology, 2021, 298, 517-530.	7.3	27
24	The bvFTD phenocopy syndrome: a case study supported by repeated MRI, [18F]FDG-PET and pathological assessment. Neurocase, 2021, 27, 181-189.	0.6	2
25	Onset of Preclinical Alzheimer Disease in Monozygotic Twins. Annals of Neurology, 2021, 89, 987-1000.	5.3	20
26	Test-Retest Variability of Relative Tracer Delivery Rate as Measured by [11C]PiB. Molecular Imaging and Biology, 2021, 23, 335-339.	2.6	2
27	Strategies to reduce sample sizes in Alzheimerâ€™s disease primary and secondary prevention trials using longitudinal amyloid PET imaging. Alzheimer's Research and Therapy, 2021, 13, 82.	6.2	14
28	Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimerâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 872-880.	1.9	17
29	Plasma amyloid-Î² oligomerization assay as a pre-screening test for amyloid status. Alzheimer's Research and Therapy, 2021, 13, 133.	6.2	19
30	Parametric imaging of dual-time window [18F]flutemetamol and [18F]florbetaben studies. NeuroImage, 2021, 234, 117953.	4.2	7
31	[¹⁸ F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers. Neurology, 2021, 97, e1017-e1030.	1.1	16
32	The approval of a disease-modifying treatment for Alzheimerâ€™s disease: impact and consequences for the nuclear medicine community. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3033-3036.	6.4	6
33	Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals. Brain Communications, 2021, 3, fcab201.	3.3	14
34	Optical coherence tomography angiography in preclinical Alzheimerâ€™s disease. British Journal of Ophthalmology, 2020, 104, 157-161.	3.9	95
35	The P2X7 receptor tracer [11C]SMW139 as an in vivo marker of neuroinflammation in multiple sclerosis: a first-in man study. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 379-389.	6.4	44
36	Why Is Amyloid-Î² PET Requested After Performing CSF Biomarkers?. Journal of Alzheimer's Disease, 2020, 73, 559-569.	2.6	8

#	Article	IF	Citations
37	Amyloidâ€Î² PET and CSF in an autopsyâ€confirmed cohort. Annals of Clinical and Translational Neurology, 2020, 7, 2150-2160.	3.7	17
38	Multitracer model for staging cortical amyloid deposition using PET imaging. Neurology, 2020, 95, e1538-e1553.	1.1	55
39	Increased 18 Fâ€flortaucipir load correlates with changes in MEG functional connectivity and network topology, as well as oscillatory slowing. Alzheimer's and Dementia, 2020, 16, e045911.	0.8	0
40	Decline in cognitively complex everyday activities accelerates along the Alzheimerâ€™s disease continuum. Alzheimer's Research and Therapy, 2020, 12, 138.	6.2	14
41	Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 3165-3175.	6.4	28
42	ATN classification and clinical progression in subjective cognitive decline. Neurology, 2020, 95, e46-e58.	1.1	97
43	Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2866-2878.	6.4	29
44	Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. Alzheimer's and Dementia, 2020, 16, 750-758.	0.8	29
45	Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimer's Research and Therapy, 2020, 12, 118.	6.2	129
46	[11C]PIB amyloid quantification: effect of reference region selection. EJNMMI Research, 2020, 10, 123.	2.5	17
47	Added value of amyloid PET in individualized risk predictions for MCI patients. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 529-537.	2.4	8
48	Amyloid imaging of dutchâ€type hereditary cerebral amyloid angiopathy carriers. Annals of Neurology, 2019, 86, 616-625.	5.3	22
49	Prognostic value of Alzheimerâ€™s biomarkers in mild cognitive impairment: the effect of age at onset. Journal of Neurology, 2019, 266, 2535-2545.	3.6	11
50	Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 492-500.	3.7	5
51	Discordant amyloid-Î² PET and CSF biomarkers and its clinical consequences. Alzheimer's Research and Therapy, 2019, 11, 78.	6.2	40
52	Harmonization of neuroimaging biomarkers for neurodegenerative diseases: A survey in the imaging community of perceived barriers and suggested actions. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 69-73.	2.4	13
53	Amyloid-Î² Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCe Project. Frontiers in Aging Neuroscience, 2019, 11, 7.	3.4	37
54	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimerâ€™s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 2019, 138, 237-250.	7.7	87

#	Article	IF	Citations
55	Retinal layer thickness in preclinical Alzheimer's disease. Acta Ophthalmologica, 2019, 97, 798-804.	1.1	36
56	High amyloid burden is associated with fewer specific words during spontaneous speech in individuals with subjective cognitive decline. Neuropsychologia, 2019, 131, 184-192.	1.6	22
57	Binding characterization of N â€(2â€chloroâ€5â€thiomethylphenyl)â€•N â€²â€(3â€[3 H] 3 methoxy phenyl)â€•N â€²â€methylguanidine ([3 H] GMOM), a nonâ€competitive N â€methylâ€Dâ€aspartate (NMDA) receptor antagonist. Pharmacology Research and Perspectives, 2019, 7, e00458.	2.1	3
58	Association of amyloid pathology with memory performance and cognitive complaints in cognitively normal older adults: a monozygotic twin study. Neurobiology of Aging, 2019, 77, 58-65.	3.1	14
59	Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimerâ€™s Disease1. Journal of Alzheimer's Disease, 2019, 68, 383-394.	2.6	14
60	PET and CSF amyloid-Î² status are differently predicted by patient features: information from discordant cases. Alzheimer's Research and Therapy, 2019, 11, 100.	6.2	21
61	AMYPAD Diagnostic and Patient Management Study: Rationale and design. Alzheimer's and Dementia, 2019, 15, 388-399.	0.8	37
62	Assessing Amyloid Pathology in Cognitively Normal Subjects Using ¹⁸F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods. Journal of Nuclear Medicine, 2019, 60, 541-547.	5.0	47
63	Evaluation of the Novel PET Tracer [11C]HACH242 for Imaging the GluN2B NMDA Receptor in Non-Human Primates. Molecular Imaging and Biology, 2019, 21, 676-685.	2.6	8
64	Prevalence of the apolipoprotein E Îµ4 allele in amyloid Î² positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.8	58
65	Association of Cerebral Amyloid-Î² Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	11.0	133
66	Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-Î² 1â€“42 Analysis Results. Clinical Chemistry, 2018, 64, 576-585.	3.2	126
67	Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. Neurology, 2018, 90, e149-e156.	1.1	103
68	First in human evaluation of [18F]PK-209, a PET ligand for the ion channel binding site of NMDA receptors. EJNMMI Research, 2018, 8, 69.	2.5	9
69	A novel partial volume correction method for accurate quantification of [18F] flortaucipir in the hippocampus. EJNMMI Research, 2018, 8, 79.	2.5	19
70	Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. BMC Geriatrics, 2018, 18, 289.	2.7	25
71	Prevalence of amyloidâ€Î² pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	5.3	132
72	Secondary prevention of Alzheimerâ€™s dementia: neuroimaging contributions. Alzheimer's Research and Therapy, 2018, 10, 112.	6.2	46

#	Article	IF	Citations
73	Clinical phenotype, atrophy, and small vessel disease in APOE Îµ2 carriers with Alzheimer disease. Neurology, 2018, 91, e1851-e1859.	1.1	46
74	The EMIF-AD PreclinAD study: study design and baseline cohort overview. Alzheimer's Research and Therapy, 2018, 10, 75.	6.2	48
75	Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. NeuroImage: Clinical, 2018, 19, 625-632.	2.7	23
76	Quantitative PET and Histology of Brain Biopsy Reveal Lack of Selective Pittsburgh Compound-B Binding to Intracerebral Amyloidoma. Journal of Alzheimer's Disease, 2018, 65, 71-77.	2.6	2
77	Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. Alzheimer's Research and Therapy, 2018, 10, 76.	6.2	87
78	Quantification of Tau Load in Alzheimerâ€™s Disease Clinical Trials Using Positron Emission Tomography. Methods in Molecular Biology, 2018, 1750, 221-229.	0.9	1
79	Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 143-151.	2.4	57
80	Quantification of Tau Load Using [18F]AV1451 PET. Molecular Imaging and Biology, 2017, 19, 963-971.	2.6	42
81	A neuroimaging approach to capture cognitive reserve: Application to Alzheimer's disease. Human Brain Mapping, 2017, 38, 4703-4715.	3.6	59
82	Arterial spin labeling-based Z-maps have high specificity and positive predictive value for neurodegenerative dementia compared to FDG-PET. European Radiology, 2017, 27, 4237-4246.	4.5	37
83	Synthesis, radiolabeling and preclinical evaluation of a [11 C]GMOM derivative as PET radiotracer for the ion channel of the N-methyl-D-aspartate receptor. Nuclear Medicine and Biology, 2017, 51, 25-32.	0.6	9
84	Human Dosimetry of the N-Methyl-d-Aspartate Receptor Ligand ¹¹C-GMOM. Journal of Nuclear Medicine, 2017, 58, 1330-1333.	5.0	2
85	Diagnostic impact of [18F]flutemetamol PET in early-onset dementia. Alzheimer's Research and Therapy, 2017, 9, 2.	6.2	98
86	Partial volume correction of brain PET studies using iterative deconvolution in combination with HYPR denoising. EJNMMI Research, 2017, 7, 36.	2.5	21
87	Model selection criteria for dynamic brain PET studies. EJNMMI Physics, 2017, 4, 30.	2.7	18
88	Heterogeneous Language Profiles in Patients with Primary Progressive Aphasia due to Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 51, 581-590.	2.6	35
89	In vivo (R)-[11C]PK11195 PET imaging of 18kDa translocator protein in recent onset psychosis. NPJ Schizophrenia, 2016, 2, 16031.	3.6	63
90	Design of the NLâ€ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 233-240.	3.7	4

#	Article	IF	Citations
91	Parametric Binding Images of the TSPO Ligand ¹⁸F-DPA-714. Journal of Nuclear Medicine, 2016, 57, 1543-1547.	5.0	23
92	Synthesis, radiolabeling and evaluation of novel amine guanidine derivatives as potential positron emission tomography tracers for the ion channel of the N-methyl-d-aspartate receptor. European Journal of Medicinal Chemistry, 2016, 118, 143-160.	5.5	10
93	Schizophrenia as a mimic of behavioral variant frontotemporal dementia. Neurocase, 2016, 22, 285-288.	0.6	12
94	Impact of New Scatter Correction Strategies on High-Resolution Research Tomograph Brain PET Studies. Molecular Imaging and Biology, 2016, 18, 627-635.	2.6	3
95	Quantification of the novel N-methyl-<scp>d</scp>-aspartate receptor ligand [¹¹C]GMOM in man. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 1111-1121.	4.3	19
96	Cerebral perfusion in the predementia stages of Alzheimerâ€™s disease. European Radiology, 2016, 26, 506-514.	4.5	99
97	Imaging of neuroinflammation in Alzheimer's disease, multiple sclerosis and stroke: Recent developments in positron emission tomography. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 425-441.	3.8	63
98	Use of amyloid-PET to determine cutpoints for CSF markers. Neurology, 2016, 86, 50-58.	1.1	54
99	Prediction of AD dementia by biomarkers following the NIAâ€AA andÂIWG diagnostic criteria in MCI patients from three European memory clinics. Alzheimer's and Dementia, 2015, 11, 1191-1201.	0.8	71
100	Quantification of ¹¹C-Laniquidar Kinetics in the Brain. Journal of Nuclear Medicine, 2015, 56, 1730-1735.	5.0	5
101	Preclinical evaluation of [18F]PK-209, a new PET ligand for imaging the ion-channel site of NMDA receptors. Nuclear Medicine and Biology, 2015, 42, 205-212.	0.6	21
102	Synthesis, structure activity relationship, radiolabeling and preclinical evaluation of high affinity ligands for the ion channel of the N-methyl-d-aspartate receptor as potential imaging probes for positron emission tomography. Bioorganic and Medicinal Chemistry, 2015, 23, 1189-1206.	3.0	14
103	The behavioural/dysexecutive variant of Alzheimerâ€™s disease: clinical, neuroimaging and pathological features. Brain, 2015, 138, 2732-2749.	7.6	397
104	The Dopamine Stabilizer (â^')-OSU6162 Occupies a Subpopulation of Striatal Dopamine D2/D3 Receptors: An [11C]Raclopride PET Study in Healthy Human Subjects. Neuropsychopharmacology, 2015, 40, 472-479.	5.4	22
105	Quantification of [¹⁸F]DPA-714 Binding in the Human Brain: Initial Studies in Healthy Controls and Alzheimer'S Disease Patients. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 766-772.	4.3	99
106	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166
107	Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939.	7.4	501
108	Visual Versus Semi-Quantitative Analysis of 18F-FDG-PET in Amnestic MCI: An European Alzheimer's Disease Consortium (EADC) Project. Journal of Alzheimer's Disease, 2015, 44, 815-826.	2.6	67

#	Article	IF	Citations
109	Widespread Disruption of Functional Brain Organization in Early-Onset Alzheimerâ€™s Disease. PLoS ONE, 2014, 9, e102995.	2.5	56
110	Is Verbal Episodic Memory in Elderly with Amyloid Deposits Preserved Through Altered Neuronal Function?. Cerebral Cortex, 2014, 24, 2210-2218.	2.9	36
111	Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. Neurology, 2014, 82, 1768-1775.	1.1	51
112	Brain network alterations in Alzheimer's disease measured by Eigenvector centrality in fMRI are related to cognition and CSF biomarkers. Human Brain Mapping, 2014, 35, 2383-2393.	3.6	108
113	Comparison of Simplified Parametric Methods for Visual Interpretation of ¹¹C-Pittsburgh Compound-B PET Images. Journal of Nuclear Medicine, 2014, 55, 1305-1307.	5.0	24
114	Synthesis and preclinical evaluation of carbon-11 labelled N-((5-(4-fluoro-2-[11C]methoxyphenyl)pyridin-3-yl)methyl)cyclopentanamine as a PET tracer for NR2B subunit-containing NMDA receptors. Nuclear Medicine and Biology, 2014, 41, 670-680.	0.6	15
115	Optimizing Patient Care and Research: The Amsterdam Dementia Cohort. Journal of Alzheimer's Disease, 2014, 41, 313-327.	2.6	307
116	Concordance Between Cerebrospinal Fluid Biomarkers and [11C]PIB PET in a Memory Clinic Cohort. Journal of Alzheimer's Disease, 2014, 41, 801-807.	2.6	109
117	O2-13-03: MILD COGNITIVE IMPAIRMENT WITH SUSPECTED NON AD PATHOLOGY (SNAP): PREDICTION OF PROGRESSION TO DEMENTIA. , 2014, 10, P194-P195.		0
118	IC-P-009: NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN. , 2014, 10, P11-P12.		0
119	IC-P-085: COMPARING ATROPHY PATTERNS IN EARLY CLINICAL STAGES ACROSS DISTINCT PHENOTYPES OF ALZHEIMER'S DISEASE. , 2014, 10, P48-P49.		0
120	O4-01-05: CLINICALLY DIAGNOSED PROBABLE AD CASES WITH A NEGATIVE AMYLOID PET SCAN: CLINICAL FINDINGS. , 2014, 10, P250-P250.		1
121	IC-P-014: USE OF CSF AMYLOID FOR DETECTING CORTICAL AMYLOID DEPOSITION: A MULTICENTER STUDY. , 2014, 10, P14-P14.		0
122	O2-05-03: USE OF CSF AMYLOID FOR DETECTING CORTICAL AMYLOID DEPOSITION: A MULTICENTER STUDY. , 2014, 10, P173-P173.		0
123	O4-01-06: NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN. , 2014, 10, P250-P251.		0
124	IC-P-013: DIAGNOSTIC VALUE OF AMYLOID IMAGING IN EARLY ONSET DEMENTIA. , 2014, 10, P14-P14.		3
125	O4-01-01: DIAGNOSTIC VALUE OF AMYLOID IMAGING IN EARLY ONSET DEMENTIA. , 2014, 10, P248-P248.		1
126	IC-P-010: CLINICALLY DIAGNOSED PROBABLE AD CASES WITH A NEGATIVE AMYLOID PET SCAN: CLINICAL FINDINGS. , 2014, 10, P12-P12.		1

#	Article	IF	Citations
127	Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer's and Dementia, 2013, 9, 414-421.	0.8	159
128	Microglial activation in Alzheimer's disease: an (R)-[11C]PK11195 positron emission tomography study. Neurobiology of Aging, 2013, 34, 128-136.	3.1	145
129	Longitudinal Amyloid Imaging Using ¹¹C-PiB: Methodologic Considerations. Journal of Nuclear Medicine, 2013, 54, 1570-1576.	5.0	148
130	O4â€03â€01: Differential impact of apolipoprotein E genotype on distributions of amyloid load and glucose metabolism in Alzheimer's disease. Alzheimer's and Dementia, 2012, 8, P618.	0.8	0
131	Day-to-Day Testâ€“Retest Variability of CBF, CMRO2, and OEF Measurements Using Dynamic 15O PET Studies. Molecular Imaging and Biology, 2011, 13, 759-768.	2.6	55
132	Detection of Alzheimer Pathology In Vivo Using Both ¹¹C-PIB and ¹⁸F-FDDNP PET. Journal of Nuclear Medicine, 2009, 50, 191-197.	5.0	119
133	Test-retest variability of quantitative [11C]PIB studies in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1629-1638.	6.4	62
134	Performance of a modified supervised cluster algorithm for extracting reference region input functions from (R)-[¹¹C]PK11195 brain PET studies. , 2008, , .		13
135	Generating parametric binding potential and volume of distribution images using a novel 2D basis function method and the two tissue compartment plasma input model. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S631-S631.	4.3	0